Roche joins race for obesity drugs with $2 7 billion thefrontierpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thefrontierpost.com Daily Mail and Mail on Sunday newspapers.
Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.
By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss pharmaceutical giant seeks to bolster its.
By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss.